In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Regulus Therapeutics Inc. (NASDAQ:RGLS) reported that Growth Equity Opportunities V, Llc has picked up 10,989,010 of common stock as of 2017-08-02.
The acquisition brings the aggregate amount owned by Growth Equity Opportunities V, Llc to a total of 10,989,010 representing a 11.3% in the company.
For those not familiar with the company, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
A glance at Regulus Therapeutics Inc. (NASDAQ:RGLS)’s key stats reveals a current market capitalization of 97.09M based on 53.18M shares outstanding and a price at last close of $0.999 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-07-25, Wright picked up 274,725 at a purchase price of $0.91 per share.This brings their total holding to 274,725 as of the date of the filing.
On the sell side, the most recent transaction saw Isis unload 111,000 shares at a sale price of $10.21. This brings their total holding to 5,173,172.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Regulus Therapeutics Inc. (NASDAQ:RGLS) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.